Growing Medical Support Helps Buoy Psychedelic Research FinancialBuzz.com News Commentary Share this article Share this article NEW YORK, Dec. 14, 2020 /PRNewswire/ -- There is a plethora of innovations that scientists and researchers have accomplished in biotechnology in recent years. Among the popular fields of study for biotech companies are gene editing, tissue engineering and regeneration, nanobiotechnology and others. In addition, new segments under the biotech umbrella are constantly being developed. For example, the medical cannabis segment has rapidly emerged in recent years, and the continuously growing acceptance of psychedelic drugs is further evidence. According to recent studies by a number of universities and research institutions, data indicates the usefulness of potential applications of psilocybin. It is a naturally occurring substance that is being examined for the potential use in the treatment of psychiatric conditions. Currently, psychedelics have been used as potential treatments for various health conditions including depression, panic disorders, post-traumatic stress disorder (PTSD), and opiate addiction. Mind Medicine (MindMed) Inc. (OTC: MMEDF) (NEO: MMED), COMPASS Pathways plc (NASDAQ: CMPS), Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), Numinus Wellness Inc. (TSX-V: NUMI) (OTC: LKYSF), Revive Therapeutics Ltd. (CSE: RVV) (OTC: RVVTF) are all working on psychedelic treatments.